Medical Ventures tests dual-purpose balloon catheter in US CAD (coronary artery disease) trial
This article was originally published in Clinica
Executive Summary
Medical Ventures has stepped closer to taking to the lucrative coronary artery disease market its artery-measuring angioplasty balloon catheter, Metricath Gemini. It has begun an FDA-approved, multicentre trial of the dual-purpose device in patients undergoing coronary artery interventions. Data from the 155-patient study will be used to support a US marketing application for the product, which was cleared for use in peripheral arteries earlier this year. The Metricath Gemini catheter allows physicians to measure arterial size and assess stent deployment, as well as dilate a vessel or post-dilate an under-deployed stent using a single cost-effective catheter, said the Richmond, British Columbia firm.